Pierre Morel

21.0k citations

125 papers · 13.3k indexed · 2 hit papers · h-index 39

Impact in

Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Hematology top 0.05%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments

Papers in

Genetics 77
- Chronic Lymphocytic Leukemia Research 64
- Myeloproliferative Neoplasms: Diagnosis and Treatment 11
Hematology 49
- Acute Myeloid Leukemia Research 20
- Chronic Myeloid Leukemia Treatments 15

Co-authors: Éric Lepage Christian Gisselbrecht Félix Reyes Pierre Fenaux Hervé Tilly Philippe Gaulard Josette Brière Bertrand Coiffier
Journals: Blood (35 papers)British Journal of Haematology (7 papers)Journal of Clinical Oncology (7 papers)Leukemia Research (6 papers)Blood Advances (3 papers)
Partner nations: France Italy United States

In The Last Decade

Pierre Morel

119 papers receiving 12.9k citations

Hit Papers

align trajectories log scale

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma 2002 · 4.0k citations

Peers

Countries citing papers authored by Pierre Morel

Since Specialization

Citations

This map shows the geographic impact of Pierre Morel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Morel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Morel more than expected).

Fields of papers citing papers by Pierre Morel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Morel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Morel. The network helps show where Pierre Morel may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Pierre Morel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Pierre Morel Line = papers co-authored together Pierre Morel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis eJHaem ·Thomas Hueso, Grégory Lazarian, Rafał Andrzej Samulski, Adrien Chauchet, Ramy Rahmé, Sabine Bréchignac, Vincent Lévy, Salomon Manier, Damien Roos‐Weil, David Ghez, Claude Gardin, Fanny Baran‐Marszak, Éric Durot, Pierre Morel, Thorsten Braun	2025	0
2	Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease Seminars in Hematology ·Prashant Kapoor, Meletios Α. Dimopoulos, Stephen M. Ansell, Efstathios Kastritis, Ranjana H. Advani, Éric Durot, Pierre Morel, Charalampia Kyriakou, Roman Hájek, Daniela Drandi, Jithma P. Abeykoon, Signy Chow, Zhitong Xin, Christopher J. Patterson, Jeffrey Matous, Christian Buske, Steven P. Treon, Marie José Kersten	2025	1
3	Waldenström’s macroglobulinemia: The LYSA pragmatic guidelines European Journal of Cancer ·Damien Roos‐Weil, Cécile Tomowiak, Stéphanie Poulain, Florence Nguyen‐Khac, T. Caponio, Marine Armand, Thérèse Aurran, Éric Durot, Keiko Furuta-Okamoto, Bénédicte Hivert, Kamel Laribi, 一成樋口, Stéphane Leprêtre, C.H. Chaing, Lis Sreynith, Laurence Simon, Véronique Leblond, Pierre Morel, Olivier Tournilhac	2025	0
4	Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia Annals of Hematology ·Cécile Tomowiak, Stéphanie Poulain, 沈国征, Pierre Feugier, Charles Herbaux, Beatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Jane Joyce, Damien Roos‐Weil, José Miguel Torregrosa Diaz, Sylvie Chevret, Véronique Leblond, (unknown)	2024	2
5	Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia Hematology/Oncology Clinics of North America ·Dipti Talaulikar, Cécile Tomowiak, Elise Toussaint, Pierre Morel, Prashant Kapoor, Jorge J. Castillo, Alain Delmer, Éric Durot	2023	3
6	Transformed Waldenström Macroglobulinemia: Update on Diagnosis, Prognosis and Treatment SHILAP Revista de lepidopterología ·Éric Durot, Cécile Tomowiak, Elise Toussaint, Pierre Morel, Dipti Talaulikar, Prashant Kapoor, Jorge J. Castillo, Alain Delmer	2022	1
7	Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia Blood Advances ·Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Beatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Justin Morgan, Damien Roos‐Weil, Sylvie Chevret, Véronique Leblond	2021	21
8	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III) Haematologica ·Arnaud Jaccard, Raymond L. Comenzo, Parameswaran Hari, Philip N. Hawkins, Murielle Roussel, Pierre Morel, Edward S Cobb, Jean‐Luc Pellegrin, Estibaliz Lazaro, Dania Mohty, P. Mercié, Л.В. Терентьева, JD Gillmore, David Lavergne, Frank Bridoux, Ashutosh Wechalekar, Ravi Seshu Annem	2014	85
9	International prognostic scoring system for Waldenström macroglobulinemia Blood ·Pierre Morel, Alain Duhamel, Paolo G. Gobbi, Meletios Α. Dimopoulos, Madhav V. Dhodapkar, Jason McCoy, John Crowley, Enrique M. Ocio, Ramón García‐Sánz, Steven P. Treon, Véronique Leblond, Robert A. Kyle, Bart Barlogie, Giampaolo Merlini	2009	228
10	Balancing Risk Versus Benefit in the Treatment of Waldenström's Macroglobulinemia Patients with Nucleoside Analogue–Based Therapy Clinical Lymphoma & Myeloma ·Xavier Leleu, Jérôme Tamburini, Aldo M. Roccaro, Pierre Morel, Jacob D. Soumerai, Vincent Lévy, Mathieu Wémeau, Aliyah Rumini Larasati, Stéphanie Poulain, Zachary R. Hunter, Irene M. Ghobrial, Steven P. Treon, Véronique Leblond	2009	20
11	Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA) Annals of Oncology ·Hervé Ghesquières, Céline Ferlay, Catherine Sebban, David Pérol, André Bosly, Olivier Casasnovas, Oumédaly Reman, Bertrand Coiffier, Hervé Tilly, Pierre Morel, Éric Van Den Neste, Philippe Colin, Corinne Haïoun, Pierre Biron, Jean‐Yves Blay	2009	49
12	Increased trisomy 12 frequency and a biased IgVH 3–21 gene usage characterize small lymphocytic lymphoma Leukemia Research ·Agnès Daudignon, Stéphanie Poulain, Pierre Morel, Dominique Penther, Françoise Parmentier, B. Bouchindhomme, José Fernandes, Patrick Duthilleul, Christian Bastard	2009	13
13	Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2 Annals of Oncology ·Pierre Morel, Philippe Gaulard, Christian Gisselbrecht, Christophe Fermé, Gilles Salles, Hervé Tilly, Josette Brière, MC Copin, P Lederlin, Olivier Hermine, Ivan Théate, Corinne Haïoun, Nicolas Mounier	2007	5
14	High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma Bone Marrow Transplantation ·S. Oro, H. Bachelez, O Vérola, Célèste Lebbé, Jean Pierre Marolleau, Christophe Hennequin, Louis Dubertret, Pierre Morel, Christian Gisselbrecht, Pauline Brice	2004	18
15	Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies Bone Marrow Transplantation ·Sophie Park, Pauline Brice, Günther Öhlschläger, D. Simon, Philippe Rousselot, Haj Mohammad Hassani Ravari Mahdieh, Pierre Morel, J. Kamath, C Gisselbrecht	2000	24
16	Translocation (3;13)(q27;q14): A Nonrandom and Probably Secondary Structural Change in Non-Hodgkin Lymphomas Cancer Genetics and Cytogenetics ·Jean-Luc Laı̈, Agnès Daudignon, Jean‐Pierre Kerckaert, Sylvie Galiègue‐Zouitina, Laurence Detourmignies, Pierre Morel, F Bauters, Pierre Fenaux	1998	7
17	Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniques British Journal of Haematology ·Pierre Morel, Christophe Declercq, Mohamed Hebbar, F Bauters, Pierre Fenaux	1996	38
18	Long-term outcome of follicular low-grade lymphoma a report of 91 patients Annals of Hematology ·Pierre Morel, Brigitte Dupriez, 赵秀英, Bernard Gosselin, Ignacio Fernández de Mata, MA Adedigba, F Bauters	1993	19
19	High incidence of lymphoid infiltration on labial salivary gland biopsy in non‐Hodgkin's lymphomas: clinical implications British Journal of Haematology ·Pierre Morel, I. Quiquandon, Anne Janin, Brigitte Dupriez, B Desablens, Bernard Gosselin, F Bauters	1993	8
20	Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. PubMed ·Pierre Fenaux, Claude Preudhomme, JL Laï, I. Quiquandon, Philippe Jonveaux, M Vanrumbeke, D. P. Khasanova, Pierre Morel, Loucheux-Lefebvre Mh, F Bauters	1992	122

About Pierre Morel

Pierre Morel is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Nephrology and Oncology, having authored 125 papers that have together received 13.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (71 papers), Chronic Lymphocytic Leukemia Research (64 papers), Acute Myeloid Leukemia Research (20 papers), Chronic Myeloid Leukemia Treatments (15 papers), Acute Lymphoblastic Leukemia research (14 papers), Viral-associated cancers and disorders (13 papers), Immunodeficiency and Autoimmune Disorders (13 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers). The work is most often cited by research in Genetics (5.8k citations), Hematology (5.7k citations), Pathology and Forensic Medicine (6.2k citations), Oncology (4.1k citations) and Neurology (1.7k citations). Pierre Morel has collaborated with scholars based in France, Italy and United States. Frequent co-authors include Éric Lepage, Christian Gisselbrecht, Félix Reyes, Pierre Fenaux, Hervé Tilly, Philippe Gaulard, Josette Brière, Bertrand Coiffier, P Lederlin and Gilles Salles. Their work appears in journals such as Blood, British Journal of Haematology, Journal of Clinical Oncology, Leukemia Research and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact